Nanobody affinity maturation using phage display selection
Ended Purchase Order Awarded Last action
- Contract number
- 75N91025P00452
- Awardee
-
Creative Biolabs Inc. UEI V595TMBX2117
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $112,658
Award facts
- Opportunity
-
- Nanobody Affinity Maturation using Phage Display Selection Pre-Solicitation · 75N91025Q00049 · Posted Jul 18, 2025
- Contract value 100% obligated
- $112,658.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- East Yaphank, NY 11967, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
This is a $112,658 firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI) to Creative Biolabs Inc., a biotechnology and pharmaceutical services company located in Shirley, New York. The contract is for specialized nanobody affinity maturation services using phage display library construction and selection, specifically targeting an anti-human BCMA nanobody for multiple myeloma applications. The objective is to deliver five affinity-optimized nanobody sequences with sufficient purified protein for in vitro and in vivo testing, with at least one clone demonstrating a minimum 10-fold improvement in binding affinity over the parental nanobody. This procurement does not utilize any set-aside designations and was structured as a sole-source acquisition based on Creative Biolabs' proprietary knowledge and prior work providing the BCMA-targeting nanobody used in NCI's proof-of-concept studies. The contract has a base period of performance of six months, with an ultimate completion date of March 14, 2026.
Quick answers
Who was awarded contract 75N91025P00452?
75N91025P00452 was awarded to Creative Biolabs Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025P00452 worth?
The government has obligated $112,658 on 75N91025P00452.
Was contract 75N91025P00452 competed?
The extent of competition for 75N91025P00452 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award